6094-60-6

Basic information

• Product Name: 1-BENZYL-4-CYANO-4-HYDROXYPIPERIDINE
• Synonyms: N-BENZYL-4-CYANO-4-HYDROXYPIPERIDINE;1-BENZYL-4-CYANO-4-HYDROXYPIPERIDINE;1-Benzyl-4-hydroxyisonipecotonitrile;1-benzyl-4-hydroxypiperidine-4-carbonitrile;1-BENZYL-4-CYANO-4-HYDROXYPIPERIDINE,98%;4-Hydroxy-1-(phenylmethyl)-4-piperidinecarbonitrile;1-Benzyl-4-cyano-4-hydroxypiperidine HCl
• CAS NO: 6094-60-6
• Molecular Formula: C₁₃H₁₆N₂O
• Molecular Weight: 216.28
• EINECS: 228-043-2
• Mol File: 6094-60-6.mol
• Article Data: 14

Chemical Properties

• Melting Point: 175-177 °C (dec.)(lit.)
• Boiling Point: 356.7°C (rough estimate)
• Flash Point: 195.4 °C
• Appearance: Yellow to beige/Crystalline Powder and Chunks
• Density: 1.0590 (rough estimate)
• Vapor Pressure: 4.22E-07mmHg at 25°C
• Refractive Index: 1.6450 (estimate)
• PKA: 11.01±0.20(Predicted)
• BRN: 476287
• CAS DataBase Reference: 1-BENZYL-4-CYANO-4-HYDROXYPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-4-CYANO-4-HYDROXYPIPERIDINE(6094-60-6)
• EPA Substance Registry System: 1-BENZYL-4-CYANO-4-HYDROXYPIPERIDINE(6094-60-6)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36
• RIDADR: 3276
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 6094-60-6(Hazardous Substances Data)

Usage

Chemical Properties

yellow to beige crystalline powder and chunks

Uses

1-Benzyl-4-hydroxypiperidine-4-carbonitrile is used in preparation of Isoxazole Carboxamide compounds useful in treatment of hearing loss and balance disorders.

InChI:InChI=1/C13H16N2O/c14-11-13(16)6-8-15(9-7-13)10-12-4-2-1-3-5-12/h1-5,16H,6-10H2

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 7677-24-9 trimethylsilyl cyanide 
• 151-50-8 potassium cyanide 
• 143-33-9 sodium cyanide 
• 773837-37-9 sodium cyanide 

Downstream Products

• 235100-94-4 1-benzyl-4-cyano-4-methanesulfonyloxypiperidine 
• 27771-25-1 1-benzyl-4-hydroxypiperidine-4-carboxamide 
• 13801-04-2 1-benzyl-4-morpholin-4-yl-piperidine-4-carbonitrile 
• 23804-68-4 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine 
• 1262988-71-5 8-Benzyl-3-(4-isopropyl-phenyl)-1-oxa-3,8-diaza-spiro[4.5]decane-2,4-dione 
• 693285-66-4 4-hydroxypiperidine-4-carboxamide 
• 495415-09-3 1-tert-butyl 4-methyl 4-hydroxypiperidine-1,4-dicarboxylate 
• 84254-97-7 1'-benzyl-octahydro-[1,4']bipyridinyl-4'-carbonitrile 
• 60437-24-3 [8-benzyl-3-(4-chloro-phenyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-4-ylidene]-(4-chloro-phenyl)-urea 
• 177948-01-5 [[4-hydroxy-1-(phenylmethyl)-4-piperidinyl]methyl]carbamic acid 1,1-dimethylethyl ester 
• 177948-02-6 4-[(t-butoxycarbonylamino)methyl]-4-hydroxypiperidine 
• 23781-00-2 ethyl 1-benzyl-4-hydroxypiperidine-4-carboxylate 
• 1538608-38-6 N-(2-aminophenyl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 
• 1538608-37-5 N-(2-amino-5-(1-methyl-1H-imidazol-4-yl)phenyl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 

Relevant articles and documents

ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF

A compound of Formula (I) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: Formula (I) wherein R1 and Y are as defined herein.

Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists

Mineralocorticoid receptor (MR) antagonists continue to be a prevalent area of research in the pharmaceutical industry. Herein we report the discovery of various spirooxindole and dibenzoxazepine constructs as potent MR antagonists. SAR analysis of our spirooxindole hit led to highly potent compounds containing polar solubilizing groups, which interact with the helix-11 region of the MR ligand binding domain (LBD). Various dibenzoxazepine moieties were also prepared in an effort to replace a known dibenzoxepane system which interacts with the hydrophobic region of the MR LBD. In addition, an X-ray crystal structure was obtained from a highly potent compound which was shown to exhibit both partial agonist and antagonist modes of action against MR.

ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE

Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.